Eli Lilly and Rigel Pharmaceuticals broke the remainder of their RIPK1 alliance, extending a pattern of large-deal pullbacks in a crowded inflammation and oncology target space. The separation follows Lilly’s earlier decision to scrap the central nervous system-focused portion of the deal. In parallel, Gilead and Arcus terminated additional TIGIT programs after a Phase 3 futility outcome, discontinuing domvanalimab combination work in metastatic non-small cell lung cancer and ending related trials. Arcus said the independent data panel concluded the study comparison versus Merck’s Keytruda plus chemotherapy was futile. Together, the exits underscore how late-stage outcomes continue to reshape platform bets, reduce commitments, and shift development resources toward faster-moving or better-validated pathways.